John Sourbeer
Stock Analyst at UBS
(0.78)
# 3,953
Out of 4,981 analysts
39
Total ratings
36.84%
Success rate
-16.75%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QGEN Qiagen | Maintains: Neutral | $48 → $50 | $45.28 | +10.42% | 5 | Aug 7, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $285 → $320 | $253.50 | +26.23% | 4 | Jul 25, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $175.01 | +37.14% | 2 | Jul 25, 2025 | |
| CYRX Cryoport | Maintains: Buy | $10 → $11 | $8.64 | +27.31% | 6 | Apr 1, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $26.42 | -11.05% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $28.57 | +57.51% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.17 | +70.94% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $95.12 | +52.44% | 3 | Nov 5, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $490.64 | -2.17% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $30.91 | +229.99% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $12.64 | +295.57% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $133.73 | -4.28% | 2 | Jul 27, 2022 |
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $48 → $50
Current: $45.28
Upside: +10.42%
West Pharmaceutical Services
Jul 25, 2025
Maintains: Buy
Price Target: $285 → $320
Current: $253.50
Upside: +26.23%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $175.01
Upside: +37.14%
Cryoport
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $11
Current: $8.64
Upside: +27.31%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $26.42
Upside: -11.05%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $28.57
Upside: +57.51%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.17
Upside: +70.94%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $95.12
Upside: +52.44%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $490.64
Upside: -2.17%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $30.91
Upside: +229.99%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $12.64
Upside: +295.57%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $133.73
Upside: -4.28%